Suven Life Sciences Limited (BOM:530239)
India · Delayed Price · Currency is INR 279.35
+12.45 (4.66%)
At close: May 29, 2026
Suven Life Sciences Revenue
In the fiscal year ending March 31, 2026, Suven Life Sciences had annual revenue of 71.15M INR with 6.89% growth. Suven Life Sciences had revenue of 15.20M in the quarter ending March 31, 2026, with 3.62% growth.
Revenue
71.15M
Revenue Growth
+6.89%
P/S Ratio
1,018.60
Revenue / Employee
515.56K
Employees
138
Market Cap
72.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 71.15M | 4.59M | 6.89% |
| Mar 31, 2025 | 66.56M | -50.37M | -43.08% |
| Mar 31, 2024 | 116.93M | -19.02M | -13.99% |
| Mar 31, 2023 | 135.95M | 16.44M | 13.76% |
| Mar 31, 2022 | 119.51M | -21.23M | -15.08% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 23.19B |
| Neuland Laboratories | 20.23B |
| Shilpa Medicare | 15.49B |
| Bajaj HealthCare | 6.11B |
| NGL Fine-Chem | 5.01B |
| Aarey Drugs & Pharmaceuticals | 3.91B |
| Sai Parenteral's | 3.81B |
| Anlon Healthcare | 1.72B |
Suven Life Sciences News
- 14 days ago - Suven Life Sciences shares rally over 17% today; Details here - Business Upturn
- 4 months ago - Pharma sector stocks today, Feb 4: Suven Life Sciences jumps 9%, Aarti Drugs falls 6%, Shilpa Medicare up 2.80%, Mankind Pharma down 2.92% - Business Upturn
- 6 months ago - Suven Life Sciences achieves 100% enrollment for Phase-2b Trial of Ropanicant for major depressive disorder - Business Upturn
- 1 year ago - Suven Life Sciences shares surge over 8% after clinical trial update - Business Upturn
- 1 year ago - Suven Life Sciences initiates Phase-1 clinical trial for SUVN-I6107 - Business Upturn
- 1 year ago - Suven Life Sciences reports positive Phase-2a results for Ropanicant in treating Major Depressive Disorder - Business Upturn
- 1 year ago - Suven Life Sciences announces FDA acceptance of Investigational New Drug - Business Upturn